Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.

Aurélien AmiotMelanie SerreroLaurent Peyrin BirouletJerome FilippiBenjamin Pariente Xavier Roblin Anthony BuissonCarmen StefanescuCaroline Trang-PoissonRomain AltweggPhilippe MarteauThibaud VaysseAnne BourrierStephane NanceyDavid Laharie Matthieu AllezGuillaume SavoyeJacques MoreauLucine VuittonStephanie ViennotGuillaume BouguenVered AbitbolMathurin FumeryCharlotte GagniereYoram Bouhniknull null

Published in: Alimentary pharmacology & therapeutics (2019)

Vedolizumab is able to maintain steroid-free clinical remission in patients with UC and CD up to week 162. Loss of response resulting in discontinuation of vedolizumab occurred in 10% of patients per year.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
rheumatoid arthritis
systemic lupus erythematosus